J&J considering sale of diagnostic business

Johnson & Johnson (NYSE:JNJ) said in an update for its Medical Devices & Diagnostics (MD&D) segment that it will evaluate strategic options for its Ortho-Clinical Diagnostics business, including a possible sale or spinout. On a conference call to discuss the pharma's 4Q12 earnings, CEO Alex Gorsky said J&J made the decision after a portfolio review, noting that Ortho-Clinical Diagnostics does not have a competitive market share. Ortho-Clinical Diagnostics markets diagnostics to screen, diagnose and monitor diseases for the transfusion community, with a focus on hospitals, laboratories and blood centers. J&J does not break out sales of the business. ...